Keyuan Pharmaceutical issued an earnings forecast, expecting net profit attributable to shareholders of the listed company for the first half of 2026 to be between 60 million and 65 million yuan, representing a year-on-year increase of 40.57% to 52.29%. The profit growth is mainly driven by the company's intensified efforts in developing the formulation market, higher sales of new products, and improved gross margins on formulation products through internal management optimization and cost reduction and efficiency enhancement. In addition, the reversal of a portion of non-operating expenses following a litigation settlement at a subsidiary also contributed to the profit increase.
Shandong Keyuan Pharmaceutical Co. Ltd. ACompany expects net profit to rise 40.57%–52.29% YoY due to higher sales, improved margins, and litigation settlement reversal.